Paradigm Health acquired Flatiron Health’s clinical research business and entered a multiyear collaboration to integrate Paradigm’s trial‑support infrastructure into Flatiron’s OncoEMR oncology electronic medical record. The deal grants Paradigm access to Flatiron’s clinical research solutions, site network and community oncology practices to expand trial access and run embedded Phase IV and post‑approval studies. Flatiron CEO Nathan Hubbard described the tie‑up as combining AI‑powered trial infrastructure with Flatiron’s network to accelerate clinical research and post‑market evidence generation. Financial terms were not disclosed; both companies emphasized the aim of streamlining sponsor access to academic and community oncology sites. Clarification: embedding clinical trials in routine care uses EHR integration and site networks to reduce enrollment friction and enable real‑world evidence collection alongside standard treatment workflows.